https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25075 Wed 11 Apr 2018 12:27:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15127 Wed 11 Apr 2018 12:25:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31397 IL1R1, IL1R2, and IL1RN), and signaling molecules (IRAK2, IRAK3, and PELI1), were measured in sputum using real-time quantitative polymerase chain reaction. Mediators were compared between the frequent (≥2 exacerbations in the 12 months) and infrequent exacerbators, and the predictive relationships investigated using receiver operating characteristic curves and area under the curve (AUC) values. Results: Of the 95 participants, 89 completed the exacerbation follow-up, where 30 participants (n=22 COPD, n=8 asthma) had two or more exacerbations. At the baseline visit, expressions of IRAK2, IRAK3, PELI1, and IL1R1 were elevated in participants with frequent exacerbations of both asthma and COPD combined and separately. In the combined population, sputum gene expression of IRAK3 (AUC=75.4%; P<0.001) was the best predictor of future frequent exacerbations, followed by IL1R1 (AUC=72.8%; P<0.001), PELI1 (AUC=71.2%; P<0.001), and IRAK2 (AUC=68.6; P=0.004). High IL-1 pathway gene expression was associated with frequent prior year exacerbations and correlated with the number and severity of exacerbations. Conclusion: The upregulation of IL-1 pathway mediators is associated with frequent exacerbations of obstructive airway disease. Further studies should investigate these mediators as both potential diagnostic biomarkers predicting at-risk patients and novel treatment targets]]> Thu 28 Oct 2021 13:03:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19962 Sat 24 Mar 2018 07:58:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23529 Sat 24 Mar 2018 07:13:47 AEDT ]]>